  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371082]’s Disease   Principal Investigator:  [INVESTIGATOR_371052], DO     Division of Gastroenterology, Hepatology and Nutrition     Children’s Hospi[INVESTIGATOR_6684]     [ADDRESS_464237]., 7NW26     Philadelphia, PA [ZIP_CODE]     ([PHONE_7663]     [EMAIL_7134]  Sub-Investigators:  Gary D. Wu, MD     James D. Lewis, MD, MSCE  Funding Sponsor:  The Broad Medical Research Program at CCFA  Investigational Product: Neomycin, vancomycin, ciprofloxacin, fluconazole, polyethylene glycol 3350, promethazine   IRB Number:   823635  IND/IDE Number:  IND Exemption granted by [CONTACT_371083]: 2015-10-13 v1.0 Amended: v2.0.20160502 Amended: v3.0.20160623 Amended: v4.0.20160729 Amended: v5.0.20160810 Amended: v6.0.20160920 Amended: v7.0.20170210 Amended: v8.0.20170313 Amended: v9.0.20170512 Amended: v10.0.[ADDRESS_464238]	of	Abbreviations	...........................................................................................................................	v	Study	Summary	.....................................................................................................................................	1	Background	and	Study	Rationale	....................................................................................................	3	Introduction	......................................................................................................................................................	3	1.1	Background	and	Relevant	Literature	...........................................................................................	3	1.1.1	Inflammatory	Bowel	Disease:	Current	Therapi[INVESTIGATOR_371053]	.........................	3	1.1.2	History	of	Gut	Microbiota-Targeted	Therapi[INVESTIGATOR_371054]	....................................................................	4	1.1.3	Preliminary	Data	.............................................................................................................................................	5	1.2	Investigational	Regimen	and	Rationale	.......................................................................................	7	2	Study	Objectives	............................................................................................................................	8	2.1	Primary	Objective	................................................................................................................................	8	2.2	Secondary	Objectives	.........................................................................................................................	8	3	Investigational	Plan	......................................................................................................................	8	3.1	General	Design	......................................................................................................................................	8	3.1.1	Screening	Phase	...............................................................................................................................................	8	3.1.2	Intervention	Phase	..........................................................................................................................................	9	3.1.3	Optional	Intervention	Extension	Phase	(14	day	repeat	drug	regimen)	......................................	9	3.1.4	Follow	Up	Phase	.............................................................................................................................................	10	3.2	Study	Endpoints	.................................................................................................................................	10	3.2.1	Primary	Study	Endpoints	............................................................................................................................	10	3.2.2	Secondary	Study	Endpoints	.......................................................................................................................	10	4	Study	Population	and	Duration	of	Participation	.............................................................	10	4.1	Inclusion	Criteria	...............................................................................................................................	10	4.2	Exclusion	Criteria	..............................................................................................................................	11	4.3	Participant	Recruitment	.................................................................................................................	12	4.4	Duration	of	Study	Participation	....................................................................................................	12	4.5	Total	Number	of	Participants	and	Sites	.....................................................................................	12	4.6	Vulnerable	Populations:	..................................................................................................................	[ADDRESS_464239]	..........................................................................	14	6	Study	Procedures	.......................................................................................................................	15	Table	1:	Schedule	of	Study	Procedures	..................................................................................................	15	
Holiday Study  Page iii  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  6.1	Screening	Phase	(Visit	0)	................................................................................................................	16	6.2	Enrollment	Phase	(Visit	1)	.............................................................................................................	16	6.3	Intervention	Phase	(Days	1-15	including	Visits	2-4):	In-person	Study	Visits	...............	17	6.3.1	Daily	Surveys	..................................................................................................................................................	17	6.3.2	Study	Visit	2	(Day	5)	....................................................................................................................................	17	6.3.3	Study	Visit	3	(Day	8)	....................................................................................................................................	17	6.3.4	Study	Visit	4	(Day	15)	.................................................................................................................................	18	6.4	Follow-Up	Phase	(Days	16-	6	months	including	Visits	5-8):	Telephone	and	In-person	Study	Visits	......................................................................................................................................................	18	6.4.1	Telephone	Follow-Up:	Visit	5	(Day	22)	...............................................................................................	18	6.4.2	Study	Visit	6	(Day	29)	.................................................................................................................................	18	6.4.3	Telephone	Follow-Ups:	3	Months	&	[ADDRESS_464240]	Review	....................................................................................................................	19	7.2	Physical	Examination	.......................................................................................................................	20	7.3	Vital	Signs	.............................................................................................................................................	20	7.4	EKG	.........................................................................................................................................................	20	7.5	Laboratory	Blood	Evaluations	.......................................................................................................	20	7.6	Pregnancy	Testing	.............................................................................................................................	21	7.7	Stool	Collection,	Shippi[INVESTIGATOR_007],	and	Analysis	....................................................................................	21	7.8	Rectal	Swabs	........................................................................................................................................	21	7.9	Efficacy	Evaluations	..........................................................................................................................	22	7.9.1	HBI	and	short	CDAI	scoring	......................................................................................................................	22	7.9.2	Fecal	calprotectin	.........................................................................................................................................	22	7.9.3	High-sensitivity	C-reactive	protein	(hs-CRP)	...................................................................................	22	7.9.4	Microbial	DNA	sequencing	.......................................................................................................................	22	7.10	Safety	Evaluations	.........................................................................................................................	23	8	Statistical	Plan	.............................................................................................................................	23	8.1	Primary	Endpoint	..............................................................................................................................	23	8.2	Secondary	Endpoints	........................................................................................................................	23	8.3	Statistical	Methods	............................................................................................................................	23	8.3.1	Safety	Analysis	...............................................................................................................................................	24	9	Safety	and	Adverse	Events	......................................................................................................	25	9.1	Definitions	............................................................................................................................................	25	9.1.1	Adverse	Event	................................................................................................................................................	25	9.1.2	Serious	Adverse	Event	................................................................................................................................	25	9.2	Recording	of	Adverse	Events	.........................................................................................................	25	9.3	Relationship	of	AE	to	Study	............................................................................................................	25	9.4	Reporting	of	Adverse	Events	and	Unanticipated	Problems	................................................	25	9.4.1	Study	SAE	Notification	to	Investigator	................................................................................................	26	9.4.3	Follow-up	report	...........................................................................................................................................	27	9.4.4	Investigator	Reporting:	Notifying	the	Penn	IRB	.............................................................................	[ADDRESS_464241]	Keepi[INVESTIGATOR_007]	.....................................	28	
Holiday Study  Page iv  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  10.1	Confidentiality	................................................................................................................................	28	10.2	Data	Collection	and	Management	.............................................................................................	28	10.3	Records	Retention	.........................................................................................................................	28	11	Study	Monitoring,	Auditing,	and	Inspecting	..................................................................	28	12	Ethical	Considerations	..........................................................................................................	28	12.1	Risks	...................................................................................................................................................	29	12.2	Benefits	.............................................................................................................................................	29	12.3	Risk	Benefit	Assessment	..............................................................................................................	29	12.4	Informed	Consent	Process	/	HIPAA	Authorization	............................................................	[ADDRESS_464242]	.........................................................................................................................	30	13.3	Participants	Stipends	or	Payments	..........................................................................................	30	14	Publication	Plan	......................................................................................................................	30	15	References	.................................................................................................................................	30	16	Appendix	A:	Adverse	Reactions	.........................................................................................	33	16.1	Ciprofloxacin	...................................................................................................................................	33	16.2	Vancomycin	......................................................................................................................................	34	16.3	Neomycin	..........................................................................................................................................	34	16.4	Fluconazole	......................................................................................................................................	35	16.5	Miralax	(PEG	3350)	.......................................................................................................................	35	16.6	Promethazine	..................................................................................................................................	36	17	Appendix	B:	Investigational	Drug	Service	Documentation	......................................	37	18	Appendix	C:	CCFA-BMRP	Sponsor	Guidelines	...............................................................	[ADDRESS_464243] of Abbreviations AE   Adverse event CBC   Complete blood count CD   Crohn’s disease CDAI                              Crohn’s Disease Activity Index CHOP   The Children’s Hospi[INVESTIGATOR_371055]   C-reactive protein CTRC   Clinical and Translational Research Center EKG   Electrocardiogram ESR   Erythrocyte sedimentation rate FCP   Fecal calprotectin GI   Gastrointestinal HBI   Harvey Bradshaw Index hsCRP   High-sensitivity CRP IBD                                 Inflammatory bowel disease IBDU   Indeterminate colitis ICE   Idiopathic chronic enterocolitis IDS   Investigational Drug Service IRB   Institutional Review Board ITS   Internal Transcribed Spacer LOR   Loss of responsiveness MRN   Medical record number PEG   Polyethylene glycol PENN   University of Pennsylvania PCDAI   Pediatric Crohn’s Disease Activity Index PUCAI   Pediatric Ulcerative Colitis Activity Index SAE   Serious adverse event sCDAI   Short CDAI TUNPRC  Tulane University National Primate Center UC   Ulcerative colitis         
Holiday Study  page 1   
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371084]’s Disease Short Title Holiday IRB Number 823635 Protocol Number N/A Phase Phase II Methodology Randomized, placebo-controlled, double blind Study Duration Individual participant participation will last 6-7 months; full study procedures are expected to last 2 years. Study Center(s) University of Pennsylvania  
Objectives Primary Objective: • To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active CD that is refractory to conventional, immunosuppressive therapy.   Secondary Objective(s): • To correlate the effectiveness in reducing bacterial 16S rRNA copy number and fungal 18S rRNA copy number, with the use of the regimen in the primary objective, with improvement of disease activity in patients with CD refractory to immunosuppressive therapy. • To determine the relationship between the effectiveness of the proposed therapi[INVESTIGATOR_371056]. Number of Participants 30 participants will be enrolled with an estimated yield of 20 evaluable participants. 
Holiday Study  Page 2  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371085]: • Participants ages 18-75 • Active moderate CD defined as Harvey Bradshaw Index (HBI) ≥ 7 • Have had primary nonresponse or an initial response for 8 or more weeks, followed by [CONTACT_371086] (LOR) (self-reported worsening of symptoms for at least 7 days), to one or more of the following therapi[INVESTIGATOR_014]*: azathioprine, 6-mercaptopurine, methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab,  vedolizumab, or ustekinumab  *Must be administered at standard, therapeutic dosages   Exclusion Criteria: • Known or suspected stricturing disease producing obstructive symptoms • Known allergy or intolerance to any of the medications used in this study • Elevated creatinine • Prolonged QTc interval as seen on enrollment EKG  Investigational Product (drug, dose, route, regimen)  Vancomycin 500 mg suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14) or placebo. PRN Promethazine 12.5mg up to every four hours (Days 1-3). Duration of administration 14 days Reference therapy N/A Statistical Methodology Our estimates of efficacy will use a disease activity score (HBI) for clinical response, FCP for mucosal inflammation, and hsCRP for systemic inflammation. The two treatment groups will be compared using standard descriptive statistics. Categorical variables will be compared using Fisher’s exact test and continuous variables will be compared using the unpaired t-test or Wilcoxon rank sum test if the data are not normally distributed.  Safety Evaluations  Primary measurements that will be used to assess safety include vital signs, laboratory results, EKG for QTc interval, disease activity scores, and screening for medication side effects and adverse events. Data and Safety Monitoring Plan  Monitoring is risk based. 
Holiday Study  Page 3  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371087] 45 CFR 46, 21 CFR Parts 50, 54, 56, and Good Clinical Practice: Consolidated Guidelines approved by [CONTACT_8639] (ICH). All epi[INVESTIGATOR_48478].  This document is a clinical research protocol and the investigators will perform the study in accordance with this protocol, will obtain consent, and will report unanticipated problems involving risks to participants or others in compliance with the University of Pennsylvania Research Policies and Procedures and all federal requirements.  Collection, recording, and reporting of data will be accurate and will ensure the privacy, health, and welfare of research participants during and after the study.  Introduction Recent evidence suggesting that the commensal gut microbiota, or the “gut microbiome,” is responsible for stimulation of the intestinal immune system in inflammatory bowel disease (IBD) has caused many researchers and providers in the field to question current therapeutic approaches.  Though most IBD providers would agree that immunosuppressive medications are currently the most reliable therapi[INVESTIGATOR_014], such research indicates that if gut flora plays a role in the pathogenesis of IBD, then perhaps targeting commensal microbes rather than or in addition to the immune system would be more efficacious.   This protocol seeks to test the hypothesis that a therapeutic approach that deeply alters the composition and bacterial/fungal load of the gut microbiota will be efficacious in patients with refractory Crohn’s Disease (CD) who have primary nonresponse or secondary loss of response to conventional, immune suppressive therapi[INVESTIGATOR_014]. This study will evaluate the efficacy of a novel treatment regimen employing non-immunosuppressive medications in the management of refractory CD.  Patients will be treated with a combination of gut microbiota-targeted therapi[INVESTIGATOR_371057][1].  We believe this strategy will both treat the gut inflammation associated with IBD, as well as rescue response to biologic or immunomodulator therapi[INVESTIGATOR_014].    1.1 Background and Relevant Literature  1.1.1 Inflammatory Bowel Disease: Current Therapi[INVESTIGATOR_371058] (IBD), including CD and UC, affects approximately 1.5 million Americans and the incidence is increasing worldwide [2].  Current evidence indicates that the pathogenesis of IBD involves an inappropriate and persistent inflammatory response to the gut microbiota in genetically susceptible individuals [3].  In support of this notion, several studies utilizing animal models have shown that the development of intestinal inflammation requires microbial colonization of the gut [4, 5].  Clinical observations of IBD further implicate the role of the commensal gut microbiota, as IBD usually affects intestinal regions with the highest bacterial load, and both fecal diversion and antibiotic treatment can be effective in the management of CD [6, 7].  However, standard treatments for IBD do not focus on restoring immune tolerance to commensal microbes but rather depend on immunosuppression.  Although effective in inducing and maintaining remission for many patients, there is substantial risk of side effects associated with the use of immunosuppressive medications, namely steroids, immunomodulators (e.g., thiopurines and methotrexate) and biologics (e.g., infliximab and adalimumab) [8].  In addition, a significant proportion of patients will experience primary nonresponse or a loss of response (LOR) to immunosuppression over time in a way that cannot be explained by [CONTACT_371088] [9].  When nonresponse or LOR occurs, providers must escalate dosage or change the treatment medication(s).  Because of the limited number of medications and concern for the exhaustion of non-
Holiday Study  Page 4  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371089], maintaining patients with IBD on an effective medication for as long as possible becomes a priority of clinical care.    1.1.2 History of Gut Microbiota-Targeted Therapi[INVESTIGATOR_371059] [10-12].  For example, IL-[ADDRESS_464244] shown that antibiotics such as neomycin, ciprofloxacin, vancomycin, and metronidazole may both prevent and treat intestinal inflammation [10, 12].  However, the evidence for the effectiveness of antibiotics in the treatment of humans with IBD has historically been less robust.  Within the past several years, two meta-analyses of randomized controlled trials have documented a small but statistically significant benefit of antibiotics to induce remission in both CD and UC [13, 14].  In addition, several studies have now shown that antibiotic combination therapy significantly improves rates of remission and also steroid withdrawal in UC [15-18].    Most notably, Turner and colleagues have recently published their experience using a two- to three-week course of combination antibiotic therapy in pediatric UC and indeterminate colitis refractory to standard immunosuppressive medications [18]. Patients were treated with combination oral amoxicillin, metronidazole, and doxycycline, except in children 2-7 years old where doxycycline was substituted with ciprofloxacin, and in infants under 2 years old where doxycycline was substituted with gentamicin.  In addition, in cases of allergy the allergenic drug was substituted with gentamicin, and in hospi[INVESTIGATOR_371060]. The antibiotic regimen was definitively effective in 7/15 (47%) of patients, inducing complete clinical remission as defined by [CONTACT_371090] (PUCAI).  For the patients defined as primary responders (n=9), i.e., clinical remission at three weeks after initiating antibiotic therapy, reduction in CRP and PUCAI were statistically significant.  Finally, all patients repeatedly tested negative for fecal C. difficile and bacterial cultures indicative of developed resistance. Only one patient tested positive for CMV and was subsequently treated with ganciclovir.  These findings demonstrate the potential efficacy of an antibiotic therapeutic strategy in the treatment of refractory IBD.    Antifungals In addition to the bacterial component, there appears to be a relationship between IBD and the fungal gut microbiota. The authors of a recent study demonstrated that mice lacking Dectin-1, a C-type leptin receptor that recognizes β-glucans in the fungal cell wall, had increased susceptibility to chemically induced colitis due to their altered immunological responses to indigenous fungi [19]. Significantly, a polymorphism in the gene encoding Dectin-1 (CLEC7A) was found to be associated with a severe form of ulcerative colitis in humans [19]. A connection between high dietary concentrations of yeast and increased disease activity in patients with CD has also been suggested [20].    In terms of fungal-targeted therapi[INVESTIGATOR_371061], preliminary evidence suggests that fluconazole treatment may reduce intestinal inflammation in animal models of colitis and in patients with IBD [21]. We recently demonstrated a significant difference in the composition of the fungal microbiota in pediatric patients with IBD as compared to healthy controls [2], further suggesting a relationship between fungi and the pathogenesis of IBD.   Bowel Lavage Given the potential role of the gut microbiota in the pathogenesis of IBD, therapi[INVESTIGATOR_371062] (GI) tract have been suggested. For example, in the 1980’s, intestinal lavage with normal saline was studied in patients hospi[INVESTIGATOR_371063]. A small, controlled study demonstrated reduction in disease severity and also duration of hospi[INVESTIGATOR_059] [23, 24]. Failure to further develop bowel lavage as an independent therapeutic option is 
Holiday Study  Page 5  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371091] 2: Time course of 16S rRNA gene copy number during oral antibiotic treatment (14 days of vancomycin plus neomycin) and upon discontinuing antibiotics on day 15 compared to control. likely secondary to advancements in pharmacological therapi[INVESTIGATOR_014]. Recent evidence has indeed shown that bacterial diversity in the gut is significantly decreased following colonoscopy preparations [25].   1.1.3 Preliminary Data  Effectiveness of Antibiotics in Mouse Models versus Humans, What’s the Difference? The observation that antibiotics as currently used have only modest efficacy in the treatment of CD and UC represents a challenge to the notion that antimicrobials could be used to deplete the microbiota in patients with IBD. One possible explanation is that the use of antibiotics in animal models is more effective in reducing intestinal bacterial load in mice than in humans. Indeed, in preliminary data [3], we show that two specific oral antibiotics dramatically reduce bacterial load by [CONTACT_7809] 4 logs in mice within 72 hours, as quantified by 16S gene copy number.   
  We believe that an antibiotic therapeutic strategy capable of significantly reducing bacterial load in patients with CD will show greater levels of efficacy in the treatment of active disease than in previously reported studies [26-28]. Additionally, based on data suggesting the potential importance of gut fungi in IBD, we hypothesize that to focus exclusively on gut bacterial load may represent a missed opportunity.  Efficacy of the Holiday Regimen for Treatment of Chronic Enterocolitis in Rhesus Macaques (Macaca mulatta) Idiopathic chronic enterocolitis (ICE) is one of the most significant causes of morbidity and mortality in captive nonhuman primates and remains a diagnostic and therapeutic challenge for veterinarians working with these species.  Current evidence suggests that ICE is a multifactorial disease involving perturbations in gastrointestinal bacterial populations, as well as the response of the host immune system to these changes [29].  Our group is currently collaborating with Tulane University National Primate Center (TUNPRC) on a study where rhesus macaques with ICE and a negative stool infectious work-up (n=6 at present) were treated with an anti-microbial regimen similar to the one proposed here.  The animals receive the following regimen: 125 mg total vancomycin hydrochloride four times daily, 50 mg/kg neomycin twice daily, and fluconazole 2 mg/kg twice daily.  Therapy was administered for a total of [ADDRESS_464245] experienced no signs of diarrhea since completion of the treatment protocol.  Soft stool was observed for one day in the remaining two monkeys since completion of treatment, with normal stool observed on other days for both animals.  Based upon daily observations of mentation/behavior, activity level, and appetite as well as pre-treatment and intra-treatment CBC and serum chemistries, this treatment regimen was well-tolerated by [CONTACT_371092].    

Holiday Study  Page 6  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371093] [18] was presented at a national meeting in 2014, physicians within the CHOP Center for Inflammatory Bowel Disease have been utilizing a combination antibiotic approach clinically for patients with IBD refractory to standard therapy.  As a means of preliminary efficacy evaluation, we performed a retrospective study (CHOP IRB #15-011806) to review our experience treating refractory IBD with combination antibiotic therapy.  Information collected included patient demographics, disease characteristics, immunotherapy history, indication for antibiotic therapy, and type, dosage, and duration of antibiotics prescribed.  Eligible patients were ages 3-21 and prescribed treatment with three or more oral antibiotics concomitantly for the treatment of IBD.  Clinical outcomes were evaluated based on changes in disease activity, as measured by [CONTACT_371094]’s Disease Activity Index (PCDAI) in participants with CD, or the Pediatric Ulcerative Colitis Activity Index (PUCAI) in patients with UC or indeterminate colitis, at the time of initiation of combination antibiotic therapy and at multiple subsequent time points.  Disease morbidity outcomes were additionally measured, including referral to and/or scheduling of surgery, as well as escalation of therapy to an experimental medication.  The incidence of adverse reactions during and following combination antibiotic therapy was also assessed.   Of the enrolled patients (n=14), four participants had CD (29%) and the remainder had UC or indeterminate colitis (IBDU) (Table 1).  In [ADDRESS_464246] immunosuppressive therapi[INVESTIGATOR_371064].  Participants were prescribed combination antibiotic therapy for an average of 29.5 days (range 9-71).   TABLE 1: PEDIATRIC IBD PATIENTS TREATED AT CHOP WITH COMBINATION ANTIBIOTICS Case Number Agea IBD Type LOR to Medicationsb Antibiotic Regimenc Duration in Days Surgery Referral Experimental Therapyd Rescue of Response 1 13.2 UC IFX+MTX MAC 14 Cancelled No escalation IFX+MTX 2 12.3 UC IFX MADV 71 Delayed (96 days) n/a IFX 3 16.4 CD IFX+MTX, ADA+MTX MCV 23 n/a No escalation ADA+MTX 4 10.8 CD IFX+MTX MAC 9 Proceeded n/a n/a 5 13.1 IBDU IFX, ADA+MTX MAC 24 Cancelled n/a ADA+MTX 6 15.7 CD IFX+MTX MACV 28 n/a Escalation n/a 7 13.6 UC IFX+MTX MAC 21 n/a n/a n/a 8 18.5 UC IFX+MTX MAC 59 Cancelled No escalation n/a 9 11.5 UC IFX RCV 35 n/a n/a IFX+MTX 10 10.7 IBDU IFX+MTX, ADA MCV 19 Delayed (22 days) No escalation n/a 11 6.5 CD IFX+MTX, ADA+MTX MCV 36 n/a n/a ADA+MTX 12 16.1 CD IFX MCDV 31 n/a No escalation IFX+MTX 13 12.3 UC n/a MCV 21 n/a n/a n/a 14 10.4 UC IFX MCDV 22 Cancelled n/a n/a          aAge at initiation of antibiotic therapy  bAll demonstrated LOR; IFX=infliximab monotherapy, IFX+MTX=IFX plus methotrexate dual therapy, ADA+MTX=adalimumab plus methotrexate dual therapy cA=amoxicillin, C=ciprofloxacin, D=doxycycline, M=metronidazole, R=rifaximin, V=vancomycin  dReferral or discussion of eligibility screening for vedolizumab (Entyvio) or ustekinumab (Stelara)    Because of the limitations inherent to the review of existing medical records, disease activity scores at all study time points were not available for each participant.  However, for those participants with available 
Holiday Study  Page [ADDRESS_464247]-completion of their prescribed antibiotic combination regimen.  There were four documented adverse reactions that occurred during the course of therapy or shortly following therapy termination.  All were mild and only one was probably related to the medication regimen (black, hairy tongue); all resolved without sequelae.  There were two severe and one life-threatening adverse event; however, all occurred two weeks after termination of therapy and based on clinical expertise were unlikely related to the antibiotic therapy.  Only one additional event was possibly related to the prescribed antibiotic therapy – a vaginal yeast infection that occurred four weeks post-termination of therapy and which also resolved without sequelae.  This proposal will test the hypothesis that the gut microbiota is fundamentally involved in the perpetuation of CD that is refractory to conventional strategies and that a strategy that dramatically alters the composition and/or biomass of the gut microbiota (both bacteria and fungi) will lead to clinical improvement and reduction of inflammation.    1.[ADDRESS_464248] a “Holiday” from gut microbes that may be perpetuating the inflammatory response.  We will attempt to reduce the microbial load in the gut through an intestinal lavage followed by [CONTACT_69506]-term (14 days) treatment with broad-spectrum antibiotics with or without an antifungal.  The intestinal lavage protocol was chosen based on the standard bowel cleanse protocol utilized at The University of Pennsylvania hospi[INVESTIGATOR_371065] [30].  In our animal study above (Figure 1), we were able to significantly reduce 16S rRNA gene copy number with a combination of two oral antibiotics – neomycin and vancomycin.  In this protocol, we have adapted the regimen for human use because of the risk of ototoxicity, which is associated with long-term neomycin therapy. Thus, we will use neomycin only for the first three days and then it will be replaced with ciprofloxacin. Ciprofloxacin will be an appropriate replacement as it is well known to be deeply disruptive to the gut microbiota [4]. For the antifungal, we have chosen to use fluconazole, which is used to treat a variety of fungal infections, because it is considered to be a safer option than other systemic antifungals such as amphotericin.    We know from our animal studies that the 16S rRNA gene copy number decreases after three days of therapy and returns to baseline five days after antibiotics are discontinued. Fourteen (14) days of therapy was chosen for this study so that there would be continued suppression of bacterial load to allow sufficient time for healing of the gastrointestinal tract. We chose standard adult dosing for the treatment of systemic or gastrointestinal infections (see Section 5.1 for dosages).  Participants in this study will not be required to stop any prior medications (including immunosuppressive medications), with the exception of probiotics and antibiotics. If potential participants are on prescribed antibiotics related to their IBD, they are required to stop those antibiotics in order to participant in this study. If potential participants are on antibiotics for a non-IBD related reason, they will be required to complete their current course before being enrolled in this study. Furthermore, participants already on steroids as part of their IBD regimen will be required to maintain their dosage and regimen during the 14 days (Days 1-14) of the study drug intervention. If dosage is increased during the [ADDRESS_464249] started rescue therapy and study drugs will be stopped.  
Holiday Study  Page 8  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  2 Study Objectives 2.1 Primary Objective The primary objective of this study is to determine the efficacy of a novel gut microbiota-targeted therapeutic regimen, comprised of a bowel lavage and oral antibiotics with or without an antifungal, in the management of active CD that is refractory to conventional, immunosuppressive therapy. 2.2 Secondary Objectives The secondary objectives will be to:  • Correlate effectiveness in reducing bacterial 16S and fungal 18S rRNA gene copy number, by [CONTACT_371095], with improvement in disease activity for patients with CD refractory to immunosuppression.  • Determine the relationship between the effectiveness of the proposed therapi[INVESTIGATOR_371056]  3 Investigational Plan  3.1 General Design “Holiday” will be a randomized, placebo controlled, double blind Phase 2a trial, with an enrollment goal of [ADDRESS_464250] completed the intervention phase, if there are an acceptable number and severity of adverse events, we will submit an amendment and joint protocol application to The Children’s Hospi[INVESTIGATOR_6684] (CHOP) for an ultimate enrollment goal of [ADDRESS_464251] demonstrated nonresponse or LOR to immunosuppressive therapy, and may be facing escalation of therapy or even surgery.  Participants will be treated with bowel lavage and oral antibiotics with or without an antifungal over a period of 14 days. Clinical efficacy will be assessed at defined time points through scoring on the Harvey-Bradshaw Index (HBI) and the short Crohn’s Disease Activity Index (sCDAI), both validated measures of CD disease activity, the fecal calprotectin (FCP), a clinical marker of intestinal inflammation, and the high-sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation.  At the stool collection time points, the composition of the gut microbiota will also be determined using 16S gene qPCR, 18S gene qPCR, 16S gene sequencing, and internal transcribed spacer (ITS) gene sequencing to determine effects on bacterial and fungal load and microbiota composition. 16S gene qPCR determines bacterial load. 18S gene qPCR determines fungal load. 16S gene sequencing determines bacterial microbiota composition. ITS gene sequencing determines fungal microbiota composition. 3.1.[ADDRESS_464252], as well as physician referrals.  For participants recruited through the outpatient clinic, written informed consent will be obtained at that outpatient visit, a REDCap Screening Questionnaire will be completed together, and consequently, an enrollment Clinical and Translational Research Center (CTRC) visit will be scheduled.  Participants consented at an outpatient clinic visit will be given a stool collection kit, so that they may bring a stool sample to the CTRC visit.  For participants identified as meeting inclusion criteria for the study and referred to the study team by [CONTACT_9682], participant contact [CONTACT_371096]-screening script to obtain verbal consent. Once verbal consent is obtained, potential participants will be emailed a REDCap Screening Questionnaire. Participants who seem to meet all inclusion criteria (see Section 4.1 and 4.2) will be scheduled for a CTRC visit and will be shipped a stool collection kit via mail. Written informed consent for participants identified through physician referrals will be obtained as the first step of the enrollment CTRC visit. This same sequence of events will take place for iConnect recruits. For all participants, the enrollment CTRC visit will include a physical 
Holiday Study  Page 9  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371097] a study investigator or CTRC nurse practitioner to determine eligibility based on clinical parameters.  For eligible participants, blood and stool samples will also be obtained at the enrollment visit for baseline values.  If necessary, (no documentation of a negative test within the previous 4 weeks), the stool sample will be tested to rule out Clostridium difficile infection.  However, it will not be necessary to wait for the result of this test to begin the study regimen as vancomycin, one of the study medications, is standard treatment for C. difficile infection. If a participant tests positive for C. difficile infection at enrollment, they will be withdrawn from the study and their primary GI physician will be notified so that antibiotic therapy can be continued on a clinical basis.  The enrollment visit blood sample will also be assessed for serum creatinine to ensure no participants with impaired kidney function are actively enrolled. Female participants will have a urine pregnancy test. All participants will undergo electrocardiogram (EKG) to assess QTc interval at baseline. Participants will also be asked to complete 7 days of an online “Daily Survey” through REDCap to record their baseline symptoms before starting any study drug. 3.1.2 Intervention Phase  For participants who are fully eligible, medications will be shipped to the participant’s home address. There will be no more than 17 days between the enrollment visit and the start of the intervention phase. The antimicrobial regimen will include 3 days of vancomycin and neomycin followed by 11 days of vancomycin and ciprofloxacin. Participants will also be randomized in a double-blinded fashion to fluconazole or placebo for 14 days. See Section 5.1 for details about dose, frequency and duration of all study drugs. Promethazine can be taken on an as needed basis on Days 1-3 for nausea secondary to neomycin.  On Day 2, participants will also undergo a bowel preparation with polyethylene glycol (PEG) 3350 (see Table 5.1). On this day, the diet will be limited to clear liquids. There will be no other dietary modifications during the course of the study.  On Days 1-14, participants will record their symptoms daily through a secure, web-based portal (REDCap).  This information will be used to calculate the sCDAI score.  In– person study visits will take place on days 5, 8, and 15. The indicated clinical and laboratory parameters will be assessed at the time of these visits. See table in Section [ADDRESS_464253] results are within the normal range and/or less than 0.20 above their baseline, participants will resume study medications for the duration of the scheduled regimen, but if their levels are still elevated, they will be referred to their primary care physician (PCP) for clinical care. Events as described above will be considered an Adverse Event (AE) and there will be appropriate follow-up as detailed in Section [ADDRESS_464254] normalized.  There is a +/- [ADDRESS_464255] occur. 3.1.3 Optional Intervention Extension Phase (14 day repeat drug regimen) Participants who achieve clinical response (reduction of the HBI by 3 or more points) or clinical remission (HBI < 5) to the study intervention at Day 15, but have relapsed (HBI ≥ 7 or sCDAI ≥ 220) between days 30 and 64 (2 months), will be offered the option to repeat the 14 day study regimen. Once the study coordinator is aware of a participant’s disease relapse, the participant’s symptoms will be observed for 2 weeks through the daily survey (but on a weekly basis) before starting their extension phase to ensure relapse. Participants who repeat the regimen will not require rescreening or a repeat enrollment visit as the repeated regimen will exclude fluconazole/ placebo, eliminating the risk of a prolonged QTc interval. The PEG lavage will also be excluded. An extra telephone visit (visit 6.1) will be added to the total number of the study visits. This visit will take place at the end of the extra [ADDRESS_464256] a 3 month visit (visit 7) and the last study visit for all participants will be at [ADDRESS_464257] on Day 29.  The indicated clinical and laboratory parameters will be assessed at the time of these visits (See Table 1 in Section 6). There is a +/- 3 day window within which these two visits (Day 22 and 29) must occur. Finally, telephone follow-ups will occur at 3 months and 6 months following the intervention phase.  There will be a 14-day (2 weeks) window in which the [ADDRESS_464258] occur for the data to be included in the analysis. 3.2 Study Endpoints  3.2.1 Primary Study Endpoints The primary endpoint will be the change in disease activity, as measured by [CONTACT_371098], between the enrollment visit and Day 15. All participants who withdraw for any reason prior to day 15 will be considered treatment failures.  • Participants with an HBI < 5 at Day 15, and a FCP concentration ≤ 200 mcg/g at Day 15, will be defined as having achieved full clinical remission. • Participants with an HBI < 5 at Day 15, but with elevated FCP (i.e. > 200mcg/g), will be considered responders. • Participants with a decrease in HBI score of 3 or more points but HBI remains > 5 at Day 15, regardless of FCP concentration level, will be considered partial responders.  3.2.2 Secondary Study Endpoints Secondary endpoints will include: • The change in CRP (or hsCRP) between the enrollment visit and day 15 • Correlation of effectiveness in reducing bacterial 16S and fungal 18S rRNA copy number, by [CONTACT_371099], with improvement of disease activity in patients with CD refractory to immunosuppression. • The relationship between the effectiveness of the proposed therapi[INVESTIGATOR_371056]  • Safety and tolerability of the treatment regimen based on medication side effects and/or adverse events (AEs). 4 Study Population and Duration of Participation  4.1 Inclusion Criteria • Participant is capable of giving informed consent • Males or females 18-75 years of age • Normal kidney function (defined by [CONTACT_371100] [male: <1.27mg/dL; female: <1.03mg/dL]) 
Holiday Study  Page 11  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  • Normal AST (<41U/L), ALT (<63U/L), and alkaline phosphatase (<126U/L) • Active CD defined as HBI ≥ 7* *Patients who have a self-report HBI of at least 6 (excluding the abdominal mass component of the index, which requires a physical examination by a clinician) will be considered eligible for scheduling of an enrollment visit and will only be actively enrolled with a definite HBI score of 7 or above, inclusive of the physical examination and abdominal mass component.  • hs-CRP >10mg/L (or 1mg/dL) or fecal calprotectin (FCP) > 350mcg/g (within one month of enrollment) • Have been treated with one of the following therapi[INVESTIGATOR_014]** for at least 8 weeks with primary nonresponse or an initial response, followed by [CONTACT_371101] (self-reported worsening of symptoms for ≥ 7 days): azathioprine, 6-mercaptopurine, methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab, vedolizumab, or ustekinumab • If taking steroids, dose must be stable for at least 2 weeks prior to screening **These medications must have been administered at standard, therapeutic dosages. 4.2 Exclusion Criteria • Unwillingness to provide informed consent  • Allergy or intolerance to the medications used in this study • Pregnant or lactating females • Known or suspected stricturing disease producing obstructive symptoms • Active Clostridium difficile infection • History of cirrhosis • Baseline QTc interval on EKG > 430ms in males or > 450ms in females • Current use of antibiotics • Starting  or increasing the dose of a IBD related medication within 4 weeks of screening including: o Azathioprine or 6-mercaptopurine (6MP) o Infliximab, adalimumab, certolizumab, or golimumab o Natalizumab or vedolizumab o Methotrexate o Any 5-ASA compound (e.g. Lialda, Asacol, etc) o Prednisone, budesonide or other steroids delivered orally or rectally • Participants who, in the opi[INVESTIGATOR_871], may be non-compliant with study schedules or procedures 
Holiday Study  Page 12  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  4.3 Participant Recruitment  Potential participants will be identified through outpatient clinic schedules and physician referrals from the Hospi[INVESTIGATOR_71971] (HUP) or Penn Presby[CONTACT_24021][INVESTIGATOR_307] (PPCM). The study will also be posted on iConnect and participants may be reminded to ask their primary GI provider or contact a study team member directly about this study through blasts in the MyPennMedicine portal. The team will procure weekly patient lists from the Penn Data Analytics Center (DAC) and target this population by [CONTACT_371102]. This has been approved by [CONTACT_371103]. Lastly, the study will also be posted on the following website: http://i3studypenn.weebly.com/associated-studies.html. An IRB approved flyer may also be posted on this website. Lastly, other web-based advertising avenues may be utilized in recruitment efforts including targeted advertising through local disease/health foundations such as the Crohn’s and Colitis Foundation of America (CCFA). Recruitment will also be conducted using social media platforms such as Facebook and Twitter using IRB approved language and hashtags. If there are questions regarding initial eligibility, necessary information from the participant’s medical record will be obtained by [CONTACT_177705]/or a member of the study team. Whenever possible, for participants recruited through the outpatient clinic, written consent will be obtained at that outpatient visit, a REDCap Screening Questionnaire will be completed, and participants will be scheduled for an enrollment CTRC visit. For participants recruited through physician referrals, patients will be contact[CONTACT_371104]-screening script to obtain verbal consent. Once verbal consent is obtained, potential participants will be emailed a REDCap Screening Questionnaire. Participants who seem to meet all inclusion criteria (see Section 4.1 and 4.2) will be scheduled for a CTRC enrollment visit. Crohn's disease history will be obtained. A stool collection kit will be given to or mailed to all participants so that a sample can be brought to the enrollment CTRC visit. No samples will be received or analyzed before obtaining written consent.   All participants must provide written consent before undergoing any other study procedures. The study procedures will be explained to each participant at the time of pre-screening and written consent. If the participant agrees to further participate, the written informed consent form will be signed in-person at either the outpatient clinic visit or the enrollment CTRC visit.   4.4 Duration of Study Participation The study duration per participant will be approximately 6-8 months, with up to 30 days for screening (from telephone verbal consent to the enrollment visit), 2 weeks for the intervention phase, and up to 6 months for the follow-up phase.    Participants who meet criteria and opt to undergo the extension phase of the antimicrobial regimen will prolong their participation in the study by [CONTACT_3450] 2 weeks.  4.5 Total Number of Participants and Sites  The study will be conducted at the clinical centers at the University of Pennsylvania (HUP and PPMC).  Recruitment will stop when approximately 20 participants are fully eligible.  It is expected that approximately 30 participants will be enrolled (screened) to produce 20 evaluable participants.  4.6 Vulnerable Populations:  Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study.  5 Study Intervention 5.1 Intervention Description and Regimen Drug Dosage Form Dosage Regimen Vancomycin 500 mg oral suspension 500 mg (1 syringe) every 6 hours Days 1-14 
Holiday Study  Page 13  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371105] 500 mg tablet 1 g (2 tablets) PO every 8 hours Day 1-3 Ciprofloxacin 750 mg capsule 750 mg (1 capsule) PO every 12 hours Days 4-14 Encapsulated fluconazole or placebo capsule 100 mg tablet encapsulated 400 mg (4 capsules) PO daily Days 1-14 Miralax (PEG 3350) Powder 238 g dissolved in 64 oz liquid with electrolytes Day 2 Promethazine Tablet 12.5mg PO as needed every  4 hours Days 1-3 5.2 Randomization Stratified randomization to fluconazole versus placebo will be performed using a 1:1 ratio of treatment arms. The randomization order will be created by [CONTACT_323259]’s Investigational Drug Service (IDS) 5.[ADDRESS_464259] of all study medications and will be instructed to report any discrepancies to a member of the study team. 5.4 Storage Study medications will be prepared, stored, and dispensed by [CONTACT_371106].  5.5 Preparation and Packaging To promote participant compliance and minimize potential confusion, study medications will be packaged into 2 blister packs: one for Days 1-7 and the other Days 8-14. The rows of the blister packs will be labeled as “Day 1” “Day 2” etc., through “Day 14”, with each dose separated into blisters by [CONTACT_371107]. The vancomycin suspensions will be packaged in separate Ziploc bags per day.  Each bag will contain four syringes containing 500 mg/[ADDRESS_464260] diabetes, Crystal Lite will be required.  With the exception of vancomycin and fluconazole, all study medications will be distributed in their original formulation as per the manufacturer. For vancomycin, IDS will compound 1,120 mL of oral suspension (500 mg/20 mL concentration) drawn up into 56 syringes per participant (see Appendix B). For fluconazole, IDS will encapsulate the original formulation tablets so that they will look identical to placebo capsules. 5.6 Administration and Accountability    Participants will be provided with all study medications by [CONTACT_371108] (UPS) to their home address following the enrollment visit and consequent confirmation of their eligibility.  Participants will take all medications orally. At the final in-person study visit, all unused study medications and empty containers will be collected from each participant.   
Holiday Study  Page 14  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  5.7 Participant Compliance Monitoring At all encounters following the enrollment visit, compliance will be monitored through study staff observation of empty blister packs at each in person visit (see Section 5.7). At each in-person visit, participants will be asked to bring in their used and unused blister packs, syringes, and PEG bottle for review by [CONTACT_464].  Compliance will be reviewed with the participants at each in-person visit. 5.7.[ADDRESS_464261] be returned to Investigator or a study coordinator.    
Holiday Study  Page 15  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  5.8 Unblinding procedure  At the end of the enrollment visit, eligible participants will be randomly assigned to one of the two treatment groups (fluconazole or placebo) according to the randomization schedule generated by [CONTACT_371109]. Neither the participant, the study team, nor the clinical site personnel will know the treatment group to which any participant is randomized.    If there is a serious adverse event, which is thought by [CONTACT_371110], the principal investigator, when necessary for the safety of the participant, will unblind treatment group assignment.  The following procedures will be taken when the sponsor or principal investigator [INVESTIGATOR_371066]: The IDS will be notified by [CONTACT_371111].  IDS will unblind the treatment group assignment and provide it to the principal investigator [INVESTIGATOR_115292].  Unblinding of treatment assignment is anticipated to be an uncommon occurrence and is highly discouraged.  Unblinding should only be performed if deemed necessary for the safety of the participant.    6 Study Procedures Table 1: Schedule of Study Procedures   Screening/ Recruitment Enrollment/ Day 0 Day 5 Day 8 Day 15 Day 22 Day 29  Day 36-64 (Optional visit) 3 mos 6 mos Study Visit Visit 0 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 6.1 Visit 7 Visit 8 Phase of Study   Intervention Phase    Follow-up Phase Telephone visit X     X  X X X Web-based screening survey X          Daily Survey   X X X X X X (weekly) X (weekly) X (weekly) Medical record review X X       X X Physical exam including vital signs  X X X X  X    Urine pregnancy test for female participants  X         Stool collection for microbiome analysis  X X X X X X    Stool C. difficile toxin X (within 1 month) X (if not done within 1 month)         Rectal swabs for mucosal analysis  X  X X  X    FCP X X  X X X X    CBC (no diff)  X Blood draw to store for future X X  X    CMP  X X X  X    ESR  X X X  X    
Holiday Study  Page 16  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371112]  X use X X  X    Infliximab or adalimumab level**  X        HBI X (within 1 month) X X X X  X    EKG  X  X        **For participants on infliximab or adalimumab 6.1 Screening Phase (Visit 0) Potential participants will be identified through outpatient clinic schedules as well as physician referrals. For participants recruited through the outpatient clinic, written consent will be obtained at that outpatient visit and participants will be scheduled for an enrollment CTRC visit. Screening for these participants will proceed as follows: • Written informed consent at outpatient clinic visit • Email or complete with coordinator screening questionnaire through REDCap. If seems eligible, schedule enrollment CTRC visit  • Distribute stool kit in-person at outpatient clinic visit or via courier service (UPS)  Or for participants identified through physician referrals or iConnect, potential participants will be contact[CONTACT_371113] a pre-screening script, emailed a screening questionnaire and scheduled for an enrollment CTRC visit. Screening for these participants will proceed as follows: • Receive physician referral or iConnect alert • Contact [CONTACT_371114], obtain verbal consent, review study procedures and eligibility criteria • For applicable and interested participants, email screening questionnaire through REDCap. If seems eligible, schedule an enrollment CTRC visit • Distribute stool kit via courier service (UPS) 6.2 Enrollment Phase (Visit 1) Eligible participants will be seen by a study team investigator and study coordinator at the CTRC for the enrollment visit.  The written informed consent form may be signed at this visit if not already completed.  Enrollment will proceed as follows: • Written informed consent (if applicable) • Review and documentation of eligibility criteria  • Obtain collected stool sample (kit provided during screening phase) for analysis of C. difficile toxin, fecal calprotectin, and microbiome • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for HBI • Rectal swabs (2) for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, hsCRP, ESR, biologic levels if applicable with extra stored for future use) • Urine pregnancy test for female participants • EKG • Participant counseled to continue all current medications except probiotics • Medication education • Distribution of Gatorade or Crystal Lite (and a pi[INVESTIGATOR_39179])  On the same day as enrollment, one (1) stool collection kit will be given to each participant so that a sample can be brought to us on Day 8. 
Holiday Study  Page 17  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  6.3 Intervention Phase (Days 1-15 including Visits 2-4): In-person Study Visits Day [ADDRESS_464262] them to start taking study drugs on the upcoming Monday, Thursday, or Friday, in order to enhance compliance and ensure that in-person study visits do not fall on weekends. This was also allow coordinators to track medication packages.  6.3.1 Daily Surveys After verbal and/or written consent is obtained from participants, they will be asked to complete 7 days of online daily surveys via REDCap before Day 1 to obtain baseline data. From Day 1 through Day 29 of the study (intervention phase and first 15 days of follow-up phase), participants will complete the same daily survey through REDCap so that the study team can monitor disease activity by [CONTACT_371115].  Participants will be prompted to identify any concerns including medication side effects and/or worsening of symptoms.  From Day 30 through 6 months, the survey including disease activity questions only will be completed once weekly. On in-person study visit days, the daily survey may be completed with the study coordinator during the visit.  Survey responses will be monitored by [CONTACT_371116] a regular basis. If more than two (2) daily surveys are not completed in a week, the coordinator will contact [CONTACT_371117]/or email to ensure compliance. If a weekly survey is not completed, participants will also be contact[CONTACT_371118].  If a participant is enrolled in the study that does not have daily access to the internet and/or email, a daily survey paper diary will be provided to them at the start of their study participation. This will include all the REDCap daily (and weekly) surveys. In order to ensure compliance for this group, participants will be required to ship the completed paper surveys to the study team on a weekly basis. UPS or FedEx shippi[INVESTIGATOR_371067]. 6.3.2 Study Visit 2 (Day 5) Study Visit [ADDRESS_464263] on Day 5.  Participants will be seen at the Penn CTRC by a study coordinator and/or CTRC nurse.  The following will be required: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom history for HBI • Blood sample for future use (metabolomics and neomycin levels) • Collect stool sample (kit provided at previous visit) • Adverse event assessment (see Section 9) • Study drug compliance assessment • Update current medications log • Daily Survey (optional) 6.3.3 Study Visit 3 (Day 8) Study Visit [ADDRESS_464264] on Day 8.  Participants will be seen at the Penn CTRC by a study coordinator and/or CTRC nurse.  The following will be required: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for HBI • EKG • Rectal swab for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, hsCRP, ESR with extra stored for future use) • Collect stool sample (kit provided at previous visit) • Adverse event assessment (see Section 9) 
Holiday Study  Page 18  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  • Study drug compliance assessment • Update current medications log • Daily Survey (optional) On Day 8, one (1) stool collection kit will be given to each participant so that a sample can be brought to us on Day 15.  6.3.4 Study Visit 4 (Day 15) Study Visit [ADDRESS_464265] on Day 15.  Participants will be seen at the Penn CTRC by a study coordinator and/or CTRC nurse.  The following will be required: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for HBI • Rectal swab for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, hsCRP, ESR with extra stored for future use) • Collect stool sample (kit provided at previous visit) • Adverse event assessment (see Section 9) • Study drug compliance assessment and collect any unused study drug • Update current medications log • Daily Survey (optional)  On Day 15, two (2) stool collection kits will be given to each participant so that 1) a sample can be collected and mailed to us by [CONTACT_2006] 22 and 2) a sample can be brought to us on Day 29 (Study Visit 6). 6.4 Follow-Up Phase (Days 16- 6 months including Visits 5-8): Telephone and In-person Study Visits The follow-up phase will include Day 16 through 6 months following the end of the intervention phase.  Telephone follow-up will occur on Day 22 (see Section 6.4.1). An in-person study visit will take place on Day 29.  Day [ADDRESS_464266] symptoms in REDCap, once weekly. Telephone follow-up will occur at 3 months and 6 months following the beginning of the intervention. 6.4.1 Telephone Follow-Up: Visit 5 (Day 22) A telephone follow-up will be conducted on Day 22 by [CONTACT_9137]. During the telephone session, questions will be asked to assess the general state of their Crohn’s Disease and their current medication regimen. The coordinator will also look at their electronic medical record to record any recent surgeries, hospi[INVESTIGATOR_602], and C diff. test results since their last study visit. Participants will be reminded to ship a stool sample collected within 24 hours of this call 6.4.2 Study Visit 6 (Day 29) Visit [ADDRESS_464267] on Day 29.  Participants will be seen at the Penn CTRC by a study coordinator and investigator or CTRC nurse.  The following will be required: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for HBI • Rectal swab for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, hsCRP, ESR with extra stored for future use) • Collect stool sample (kit provided at previous in-person visit) • Adverse event assessment (see Section 9) • Study drug compliance assessment • Update current medications log 
Holiday Study  Page 19  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  • Daily Survey (optional) 6.4.3 Telephone Follow-Ups: 3 Months & 6 Months Telephone follow-up will also occur at 3 months and 6 months after the intervention phase.  For these follow-up sessions, we will allow a two-week window. During the telephone session, questions will be asked to assess the general state of their Crohn’s Disease and their current medication regimen. The coordinator will also look at their electronic medical record to record any recent surgeries, hospi[INVESTIGATOR_602], and C diff. test results since their last study visit.  6.5 Rescue Therapy If a participant’s condition worsens during the course of the study, the PI [INVESTIGATOR_371068]’s primary provider will make a decision, based on clinical expertise, to withdraw the participant from the study.  If the participant receives a rescue medication after the study intervention regimen is completed (Day 15 or later) the participant has the option to continue to participate in the study, at his or her discretion.  For participants who need to receive rescue medication(s) during Days 1-[ADDRESS_464268] not responded to therapy. With their permission, these participants will be followed to the end of the 6 month time point of the study schedule. 6.6 Participant Withdrawal  Participants may withdraw from the study at any time without prejudice to their clinical care.  They may also be discontinued from the study at the discretion of the Investigator for lack of adherence to study treatment or visit schedules, AEs, lack of response, reasons of safety, administrative reasons and/or need for rescue medication during the enrollment or intervention phase.  Participants who require rescue medication or surgery after completion of the intervention regimen (Day 15 or later) will continue to be followed by [CONTACT_371119].  It will be documented whether or not each participant completes the clinical study. If the Investigator becomes aware of any serious, related adverse events after the participant completes or withdraws from the study, they will be recorded in the adverse event log of the study. 6.[ADDRESS_464269] of elements that may be abstracted from the participant’s medical chart (either paper or electronic): • Date of birth • MRN • Mailing address • Email address • Telephone number • Sex • Race • Most recent height 
Holiday Study  Page 20  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  • Most recent weight • Crohn’s disease history (including date of diagnosis, and disease location) • Prior use of medications • Current medications • Medication allergies • Surgical history (including all surgeries regardless of relation to IBD) • Co-morbid medical conditions • History of stricturing or fistulizing disease (from review of records for history of bowel obstruction and imaging studies) • Patient report of bowel frequency • Patient report of abdominal pain • Patient report of general well-being • Most recent physical examination • Laboratory tests (including ESR, CRP, albumin, hematocrit, hemoglobin, fecal calprotectin, stool C. difficile toxin, drug levels for biologics) 7.2 Physical Examination A physical examination will be performed in order to calculate the HBI at all in-person study visits. A study investigator or CTRC nurse practitioner will document whether there is an abdominal mass (0=none, 1=dubious, 2=definite, 3=definite and tender). A study investigator or CTRC nurse practitioner will also document any extraintestinal manifestations of disease, including arthralgia, uveitis, erythema nodosum, aphthous ulcers, Pyoderma gangrenosum, anal fissure, new fistula, and/or abscess. A brief overall physical exam may also be completed with documentation being completed in EPIC by [CONTACT_371120] “out of office” encounter. A copy of this documentation should be printed out from EPIC and added to the participant’s study file. 7.3 Vital Signs Oral temperature will be obtained using a digital thermometer.  Heart rate and blood pressure will be obtained using an automated device while the patient is seated.  Height and weight will also be obtained. Height will only be measured once at the enrollment visit. All anthropometric measurements will be conducted with the participants wearing light clothing without shoes. Weight (0.1 kg) will be measured on a digital electronic scale (Seca, Munich, [LOCATION_013]), and stature (0.1 cm) on a stadiometer (Holtain, Crymych, [LOCATION_006]). Clinical anthropometric measurements taken may be used for the study as well.  7.4 EKG A 12-lead EKG will be performed by [CONTACT_371121] 0 (the enrollment visit) and on Day 8 (Visit 3). EKG is indicated because both ciprofloxacin and fluconazole carry some risk of QTc interval prolongation. The QTc interval will be assessed by a study investigator using manual determination with a caliper. A prolonged QTc interval is defined as >430msec in males and >450msec in females. Participants with a prolonged QTc interval at baseline will be excluded. Participants with a prolonged QTc interval on Day 8 will discontinue the fluconazole/ placebo aspect of the study medication regimen. The study coordinator will remove the fluconazole/ placebo from the blister pack to avoid accidental doses. 7.5 Laboratory Blood Evaluations Blood will be collected by [CONTACT_371122][INVESTIGATOR_371069] (Pepper Lab) or by [CONTACT_371123].  The following testing will be performed: • ESR  • hsCRP • CMP • CBC without differential • *Drug levels for participants on biologics stored for future testing 
Holiday Study  Page 21  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  • **Extra blood for storage for future testing * At the enrollment visit, blood will be obtained for drug level and antibody testing for patients who are being treated with infliximab or adalimumab (ARUP laboratories). Serum will be stored frozen in ARUP transport tubes. Serum will be stored for future use so that it will be possible to correlate response to this regimen with biologic drug levels and presence or absence of biologic medication antibodies. **An extra 8mL of blood will be drawn and will be stored for future metabolomics studies at the enrollment visit, day 5, day 8, day 15, and day 29. 7.[ADDRESS_464270] will be performed at the enrollment visit in the CTRC for all female participants.  7.7 Stool Collection, Shippi[INVESTIGATOR_007], and Analysis Each participant will be provided with five (5) stool collection kits to take home during the course of the study. Each kit will contain a collection hat, ice packs, shippi[INVESTIGATOR_280520], a box to hold the collection container, a specimen bag, and a prepaid shippi[INVESTIGATOR_7801] (for the one specimen that will be shipped). Each kit will also include a small spoon top vial with pre-measured ethanol to preserve the freshest stool sample. Samples being shipped with an ethanol aliquot will be appropriately packaged with an “Excepted Quantities” label. This aliquoting will be completed by [CONTACT_371124][INVESTIGATOR_21878]. Stool collection and aliquoting instructions will be provided and verbally explained to all participants in advance. The participants will also be asked to complete a form identifying their sample from the standard Bristol Stool Chart.  Participants will be instructed to collect a bowel movement at 5 time points – enrollment, Day 8, Day 15, Day 22, and Day 29. Stool samples must be collected no more than 24 hours before an in-person visit delivery time or being pi[INVESTIGATOR_371070]. The Day 22 sample will be shipped to the study team. All other samples will be delivered to the study team on the day of the in-person study visits. For Day 22, participants will be counseled that stool samples should not be collected or shipped Friday-Sunday. Alternatively, the participant may also choose to deliver the Day 22 sample to a study team member in-person.  All specimens remaining after the study is complete will be retained for possible future use unless the participant requests that the specimen be destroyed (opt-out) or it is deemed by [CONTACT_371125]. An aliquot of stool from the enrollment sample will be sent to Penn microbiology laboratory for C. difficile testing if necessary (not already obtained clinically as previously described). An aliquot of stool from each of the [ADDRESS_464271]. Gary Wu (sub-investigator). The tube containing ETOH will be stored at -80°C. The excess stool will be aliquoted as follows and stored at -80°C: 4 spoon-top tubes (Sarstedt) – 3 dry and 1 containing RNALater®, 1 coring tube (Globe Scientific) to obtain frozen stool cores for use with CryoXtract 350. All analyses will occur in [CONTACT_192437]’s laboratory or at the PennCHOP Microbiome Center. 7.8 Rectal Swabs At the enrollment visit, Study Visit 3, Study Visit 4, and Study Visit 6, participants will undergo a rectal swab for assessment of the mucosally-associated gut microbiota.  Based on results from the Stool/Swab Pi[INVESTIGATOR_799] (CHOP IRB #11-008506), differences were identified in the composition of the gut microbiota in rectal swabs as compared to traditional stool samples. Thus, we will study microbial differences between collected rectal swabs and stool samples [5].  Rectal swabs will be obtained during the physical examination by [CONTACT_371126]. Two (2) sterile swabs will be inserted 3 cm into the rectum, turned 360 degrees, removed, 
Holiday Study  Page 22  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371127] a sterile tube, and frozen at -80 degrees celcius until analysis. One (1) swab will be waved in the air and collected as a control.  For the first [ADDRESS_464272]. Wu’s laboratory for anaerobic culture. This is in order to validate microbiome PCR results with anaerobic culture.  All frozen swabs will be analyzed by [CONTACT_371128].  7.9 Efficacy Evaluations 7.9.1 HBI and short CDAI scoring The Harvey-Bradshaw Index (HBI) is a validated, non-invasive scale that is widely used in clinical trials to assess Crohn’s disease activity among adults [31, 32].  Devised as a “simple” but accurate alternative to the full Crohn’s Disease Activity Index (CDAI), which requires patients to recall and average daily symptoms over the course of a week, the HBI scale incorporates self-reported symptoms and physical examination findings for an overall score of 0 to >16 [31].  In accordance with clinical trial standards, the current study will define active disease as an HBI score ≥ 7. To be defined as having reached full clinical remission, patients must achieve an HBI score < 5, and a FCP concentration ≤ 200 mcg/g.  Participants with HBI < 5 but with elevated FCP (i.e. > 200 mcg/g) will be considered partial responders.  Participants who achieve clinical response with a reduction in HBI score of three or more, but without remission (HBI < 5), will also be considered partial responders.  The short CDAI (sCDAI), a modified, validated score of disease activity that includes only patient self-report elements [33], will be administered through the daily REDCap surveys on Day 1-29 and then weekly thereafter (see Section 6.3.1).  7.9.2 Fecal calprotectin Evidence suggests that fecal calprotectin (FCP) represents an excellent surrogate marker of intestinal inflammation and disease activity. Calprotectin is 36 kDa calcium- and zinc-binding protein that represents 60% of cytosolic proteins in granulocytes [34].  Furthermore, calprotectin is highly stable in feces when stored at room temperature for up to 1 week [6].  Clinically, the concentration of calprotectin in feces (FCP) is used as a non-invasive measure of neutrophilic infiltrate in the bowel mucosa, and thus intestinal inflammation. The correlation of decreased FCP concentration to mucosal healing has been demonstrated by [CONTACT_371129]’s disease [7]. This has been confirmed in both adult and pediatric populations with Crohn’s disease [8, 9]. A recent meta-analysis identified a cut point of 250 mcg/g as optimal to distinguish the presence or absence of endoscopi[INVESTIGATOR_371071] [40]. However, reduction in FCP is also used to assess improvement. For example, following treatment with anti-TNF therapy, FCP has been demonstrated to dramatically decline [41].   In this study, FCP concentration will be assessed using ELISA methods ( study labs). 7.9.3 High-sensitivity C-reactive protein (hs-CRP) C-reactive protein is produced mainly in hepatocytes in response to acute phase stimuli such as inflammation.  Its production is driven by [CONTACT_371130]. C-reactive protein is commonly used to screen the activity of chronic inflammatory diseases including IBD. In general, patients with CD have a high CRP when the disease is active and a normal CRP when the disease is quiescent.  High-sensitivity CRP (hs-CRP) assays measure CRP levels that were previously thought to be under detection limits.  Hs-CRP levels are thought to correlate with disease activity in IBD. Hs-CRP will be tested through Pepper Labs at the University of Pennsylvania. 7.9.4 Microbial DNA sequencing DNA will be prepared in the PennCHOP Microbiome Center. Samples will be sent to the center de-identified and coded with a study number. We will perform 16S rRNA and ITS gene sequencing to evaluate the bacterial and fungal microbiota, respectively, in stool and rectal swab samples. Isolated DNA will be quantified using the Pi[INVESTIGATOR_309688] 50 ng of DNA will be amplified.  Pyrosequencing will be 
Holiday Study  Page 23  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371131] [10].  For pyrosequencing of bacteria, primers annealing to the V1V2 region of the 16S bacterial gene will be used.  The development of the ITS1 fungal primers is described in [10].  For pyrosequencing, we will use the [COMPANY_002]/454 Genome Sequencer Junior.  Sequence data will be processed using QIIME [11]. If warranted by [CONTACT_77886], we may analyze samples further using a metagenomic approach, in which DNA samples are nebulized, ligated to linkers, and subjected to pyrosequencing (IlluminaHiSeq).  This allows enumeration of the types of genes present in a sample. To determine bacterial and fungal load, respectively, we will determine 16S and 18S gene copy number from the stool and rectal swab samples. The qPCR methods including the details of the primers as well as PCR cycling conditions have been previously described [12].  7.10 Safety Evaluations Participant safety will be monitored by [CONTACT_12902], medication side effects, vital signs, physical examinations, and laboratory data. The Principal Investigator [INVESTIGATOR_371072], nausea/vomiting, increased abdominal pain, and increased diarrhea from baseline (see Section 9).  Adverse events will be compared to all known side effects of the antimicrobials prescribed through the current study (see Appendix A). All adverse events will be tracked and assessed by [CONTACT_978]. Adverse events will be reported according to Penn Research Policy and Procedure – please see Section 9.5 for additional safety monitoring details for this study. 8 Statistical Plan 8.1 Primary Endpoint The primary endpoint will be the change in disease activity, as measured by [CONTACT_371132], between the enrollment visit and Day 15.All participants who withdraw for any reason prior to day 15 will be considered treatment failures.   • Participants with an HBI < 5 at Day 15, and a FCP concentration ≤ 200 mcg/g at Day 15, will be defined as having achieved full clinical remission. • Participants with an HBI < 5 at Day 15, but with elevated FCP (i.e. > 200mcg/g), will be considered responders. • Participants with a decrease in HBI score of 3 or more points but HBI remains > 5 at Day 15, regardless of FCP concentration level, will be considered partial responders.  8.2 Secondary Endpoints  Secondary endpoints will include the following: • The change in CRP (or hsCRP) between the enrollment visit and Day 15 • Correlation of effectiveness in reducing bacterial 16S and fungal 18S rRNA copy number, by [CONTACT_371099], with improvement of disease activity in patients with CD refractory to immunosupression. • The relationship between the effectiveness of the proposed regimen with changes to the composition of the gut microbiota • Safety and tolerability of the treatment regimen based on medication side effects and/or adverse events (AEs). 8.[ADDRESS_464273] descriptive statistics. Categorical variables will be compared using Fisher’s exact test and continuous variables will be compared using the unpaired t-test or Wilcoxon rank sum test if the data are not normally distributed.    
Holiday Study  Page 24  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371133]: clinical response, clinical remission, reduction in FCP concentration, and reduction in hsCRP. For clinical response (reduction of score on HBI by 3 or more points) we will report the proportion and binomial 95% confidence intervals. Similar methods will be used for remission (HBI < 5). Although 250 mcg/g has been recently recommended, there is no standard definition of a clinically meaningful reduction in FCP and many definitions have been used. Therefore, we will use a paired t-test (after applying a log transformation if necessary) to establish whether the FCP concentration is lower following therapy than at baseline and we will also report the proportion of patients with reduction in FCP to less than 250 mcg/g among the subset with baseline FCP > 350 mcg/g.  Similarly, there is no standard definition of a clinically meaningful reduction in hsCRP.  Therefore, we will use a paired t-test (after applying a log transformation if necessary) to establish whether the hsCRP is lower following therapy than at baseline.  As a Phase 2a study to determine the effectiveness of the two treatment arms to induce a clinical response or remission, with 20 participants, it is possible to generate the required data [43].   To detect reduction in bacterial and fungal load by 16S and 18S gene copy number we will use a paired t-test after applying a log transformation. Based on our preliminary data, we assumed that the standard deviation of change will be approximately 0.[ADDRESS_464274] 90% power, this requires only [ADDRESS_464275] deviation is greater, say 1 or 2 log, the required sample size is 5 or 13, respectively.  We will measure the Pearson’s correlation to determine the relationship between copy numbers and the outcome measures listed above (HBI, FCP, and hsCRP). If all patients do not have >2 log drop in 16S and 18S copy number, we will compare clinical remission and response among those with and without >2 log drop using Fisher’s exact test.  Our main statistical and computational tool for comparing the bacterial gut microbiota among different groups (e.g. between samples from different time points) is the phylogenetic-based method as implemented in the program UniFrac [46, 47], which measures the similarity among the community based on phylogenetic distances determined by [CONTACT_941] 16S rRNA gene sequences of different bacteria. Based on these distances, we can cluster the microbiomes using the Principal Coordinate Analysis (PCoA) along axes of maximal variance.  The significant principal components can then be compared between two groups using the two sample t-tests. Permutations can be used to obtain the p-values. Alternatively, we can compare several principal components simultaneously by [CONTACT_371134]. Specifically, we can randomize the labels of the groups and compare all distances between points that both come from the same group to all distances between points from different groups using t-tests. In such permutation test, we can obtain a nonparametric distribution of the t statistic that takes into account the correlations introduced by [CONTACT_371135]-wise distance matrix structures. For the fungal community distances, Jaccard and abundance-weighted Jaccard indices will be calculated. 8.3.1 Safety Analysis  All participants entered into the study at the enrollment visit will be included in the safety analysis. The frequencies of AEs by [CONTACT_24975], body system, severity and relationship to study drug will be summarized. SAEs (if any) will be described in detail.   AE incidence will be summarized along with the corresponding exact binomial 95% two-sided confidence intervals.  We expect that adverse events will occur because the participants included in this study will have active, refractory disease.  Thus, hospi[INVESTIGATOR_371073]-threatening events may occur.  However, we anticipate very few, if any, adverse events that are directly related to the proposed intervention.  
Holiday Study  Page 25  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  9 Safety and Adverse Events 9.1 Definitions 9.1.1 Adverse Event An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.  All AEs (including serious AEs) will be noted in the study records and on the case report form with a full description including the nature, date and time of onset, determination of non-serious versus serious, intensity (mild, moderate, severe), duration, causality, and outcome of the event. 9.1.2 Serious Adverse Event A serious adverse event (SAE) is an adverse event that, in the view of either the investigator or sponsor, results in any of the following outcomes:  • death, • a life-threatening adverse event,  • inpatient hospi[INVESTIGATOR_1081], • a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect  Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_3767] a serious adverse drug event when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. 9.[ADDRESS_464276] with the participant the Principal Investigator [INVESTIGATOR_371074], as appropriate, by [CONTACT_5148].  Information on all adverse events will be recorded immediately in the adverse event log (AE- CRF).  All clearly related signs, symptoms, and abnormal diagnostic procedures results should recorded in the log, though should be grouped under one diagnosis.  All adverse events occurring during the period will be recorded.  The clinical course of each event will be followed until resolution, stabilization, or until it has been determined that the study intervention or participation is not the cause.  Serious adverse events that are still ongoing at the end of the period will be followed up to determine the final outcome.  Any serious adverse event that occurs after the study period and is considered to be possibly related to the study intervention or study participation will be recorded and reported immediately. 9.3 Relationship of AE to Study  The relationship of each AE or SAE to the study intervention will be characterized by [CONTACT_978], with input from the study team as necessary, using one of the following terms in accordance with Penn IRB Policies: definitely related, probably related, possibly related, unlikely or unrelated.  9.[ADDRESS_464277] be completed by [CONTACT_093].  The investigator will keep a copy of this form on file at the study site.  Report SAEs by [CONTACT_371136]:  James D. Lewis, MD, MSCE Phone – ([PHONE_7664]  Cell – ([PHONE_7665]  In the event that [CONTACT_371150] cannot be reached report SAEs to  Lindsey Albenberg, DO Phone - ([PHONE_7663]  Or  Unmesha Roy Paladhi Phone – ([PHONE_7666] Cell – ([PHONE_7667]  At the time of the initial report, the following information should be provided: • Study Name • Participant number • A description of the event  • Date of onset • Current status  • The reason why the event is classified as serious Within the following [ADDRESS_464278] the understanding of the event.  Significant new information on ongoing SAEs should be provided promptly to the study investigator.  9.4.2 Penn IRB Safety and Expedited Reporting Requirements  Unanticipated Problem/Adverse Event Classification Penn IRB Reporting Requirements All Studies Research Related Unexpected Fatal/Life Threatening X X X ≤ 3 working days X X  ≤ 10 working days Other Events: • New information showing increased risk to participants • Unapproved protocol deviation to assure protection of human participants • Protocol deviation that places participants at risk or has the potential to occur again • Any serious or continuing non-compliance • Breach of confidentiality • Incarceration of participant • Withdrawal from marketing for safety concerns of the research drug, ≤ 10 working days 
Holiday Study  Page 27  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371137], or biologic  9.4.3 Follow-up report If an SAE has not resolved at the time of the initial report and new information arises that changes the investigator’s assessment of the event, a follow-up report including all relevant new or reassessed information (e.g., concomitant medication, medical history) should be submitted to the Penn IRB. The investigator is responsible for ensuring that all SAE are followed until either resolved or stable.  9.4.4 Investigator Reporting: Notifying the Penn IRB  The Investigator will promptly notify the Penn IRB of all on-site, unanticipated SAEs that are related to the research activity. Other unanticipated problems related to the research involving risk to participants or others will also be reported promptly. Written reports will be filed using the HS-ERA system and in accordance with the Penn IRB Policies (see Table 9.4.1). External SAEs that are both unexpected and related to the study intervention will be reported promptly after the Investigator receives notification.  9.5 Medical Monitoring The current study has received an Investigational New Drug (IND) Exemption from the Penn IND/IDE Support Unit within the Office of Clinical Research. As part of an established safety and monitoring plan, the Primary Investigator will monitor adverse events and unanticipated problems during the study to monitor ongoing participant safety. A Safety Officer, David S. Goldberg, MD, MSCE ([PHONE_7668]), has been identified to provide additional monitoring for the study. This individual is a board-certified gastroenterologist in adult practice who is knowledgeable in the natural history and treatment of CD, but who is not directly involved in the study and has no conflict of interest, financial or otherwise.  Following Penn IRB guidelines, all onsite, unanticipated SAEs will be reported to the Safety Officer promptly (within 3 working days) in the form of a written narrative. This will include a copy of the completed Serious Adverse Event form and any other information that will assist the understanding of the event. Significant new information for ongoing serious adverse events should be provided promptly to the study sponsor.  All other adverse events will be reported to the Safety Officer quarterly.  Based on these reports, the Safety Officer will have the authority to suspend the study and to convene a Data and Safety Monitoring Board (DSMB) as necessary.  We do not feel that a DSMB is necessary at the time of study launch given the open-label design and utilization of FDA-approved medications. This monitoring plan, in addition to screening for prolonged QTc and kidney and liver dysfunction, has been established to ensure the safety of the investigational regimen in this population.  9.5.[ADDRESS_464279] access to this information: the research team, medical staff who are directly or indirectly involved in patients’ care, and the Penn IRB.  The data shared with the PennCHOP Microbiome Center will be coded.  The results of this study may be shown at meetings or published in journals, but we will keep all identifying information private in any publication or presentation about this study.  
Holiday Study  Page [ADDRESS_464280] of 1996 (HIPAA).  Those regulations require a signed participant authorization informing the participant of the following:  • What protected health information (PHI) will be collected from participants in this study • Who will have access to that information and why • Who will use or disclose that information • The rights of a research participant to revoke their authorization for use of their PHI.   In the event that a participant revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of participant authorization.  For participants that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the participant is alive) at the end of their scheduled study period. 10.2 Data Collection and Management  In order to ensure privacy, the collection of stool will be conducted in a private bathroom within the CTRC facility or the patient’s home.  Stool and swab samples will be coded, and the processing laboratory will receive samples labeled only with the participant ID number and date of collection.  A master patient list with identifiers will be maintained by [CONTACT_978] [INVESTIGATOR_371075] a password-protected MS Excel spreadsheet saved on a secure shared research drive.  Personal health information will be collected; however all data will be coded and kept in a secure online REDCap database, separated from identifiers.  Paper records will be kept in a locked cabinet/desk in the study staff’s office.  10.[ADDRESS_464281] two (2) years after the last participant has completed the study.  11 Study Monitoring, Auditing, and Inspecting The investigator will permit study-related monitoring, audits, and inspections by [CONTACT_1383]/IRB, the sponsor, government regulatory bodies, and University compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.). The investigator will ensure the capability for inspections of applicable study-related facilities (e.g. pharmacy, diagnostic laboratory, etc.).   The Primary Investigator will monitor adverse events and unanticipated problems during the study to monitor ongoing participant safety. All SAE’s will be reported to the safety officer within mandated time frames.  Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_17256]. 12 Ethical Considerations This study is to be conducted in accordance with applicable US government regulations and international standards of Good Clinical Practice, and applicable institutional research policies and procedures.  This protocol and any amendments will be submitted to a properly constituted independent Ethics Committee (EC) or Institutional Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the study conduct.  The decision of the EC/IRB concerning the conduct of the study will be made in writing to the investigator and a copy of this decision will be provided to the sponsor before commencement of this study.  
Holiday Study  Page 29  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  12.1 Risks There are potential risks to participants who agree to participate in this trial; however, we believe that the risks are relatively small and have been minimized by [CONTACT_371138]. For participants above the age of 65, any additional risk due to Ciprofloxacin should be mitigated through the additional precautions described in Section 3.1.2. The participants will have already been refractory to at least one conventional therapy.  Many of these patients will otherwise be facing escalation of therapy to a medication that is considered experimental or will be facing surgery. We believe that the risks associated with this study are significantly less than the risks associated with surgery. The risks of each medication will be reviewed in detail as part of the consent process.    As the participants’ concurrent therapi[INVESTIGATOR_371076], the probability of harm is very low. Participants can be withdrawn from the study at any time. Additionally, if a participants’ condition worsens and a rescue therapy is deemed necessary by [CONTACT_371139], the participant will be withdrawn.  We believe that the therapeutic regimen described in this protocol is safe. These are medications that are already FDA approved for various indications. We are using standard dosing. Also, many of the medications in the proposed regimen are already utilized in children and adults with CD. Finally, in our preliminary data, we found a similar regimen to be safe in primates. 12.2 Benefits The primary potential benefit is improvement in disease activity and potential salvaged response to the prior treatment regimen (immunomodulator or biologic medication).  Additionally, in terms of indirect benefits, participation in this study will improve our understanding of the role of the gut microbiota in the inflammatory bowel diseases. The risks of participating in this study are outweighed by [CONTACT_371140]. Finally, the new knowledge about the gut microbiota that stands to be gained presents an additional benefit of this study, further contributing to the favorable balance of potential benefits to possible harms. 12.[ADDRESS_464282] of this study. 12.4 Informed Consent Process / HIPAA Authorization  Information about study participants will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those regulations require a signed participant authorization informing the participant of the following:  • What protected health information (PHI) will be collected from participants in this study  • Who will have access to that information and why  • Who will use or disclose that information  • The rights of a research participant to revoke their authorization for use of their PHI   In the event that a participant revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of participant authorization.  All data related to this trial will be recorded using the patients’ assigned unique study number. Data will be reported only in a confidential manner such that the personal identity of any participant will not be identifiable. All study data will be maintained under a double locked system, such as a locked closet within a locked office or on a password protected computer in a locked office. Data will be entered into a secure REDCap database accessed on a password-protected computer. 
Holiday Study  Page [ADDRESS_464283] with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by a properly constituted Conflict of Interest Committee with a Committee-sanctioned conflict management plan that has been reviewed and approved by [CONTACT_28833]. All University of Pennsylvania investigators will follow the University conflict of interest policy. 13.3 Participants Stipends or Payments Participants are not provided compensation for their participation in this study. However, in order to defray their parking and/ or travel costs, participants will receive $7 per in-person visit. This is equivalent to the amount required for parking in the PCAM parking garage for up to 3 hours (which is more than the length of each study visit) with validation from the PCAM information desk. [ADDRESS_464284] results and all data derived from the study.  15 References 1. Lewis, J.D., The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology, 2011. 140(6): p. 1817-1826 e2. 2. Molodecky, N.A., et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46-54 e42; quiz e30. 3. Sartor, R.B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol, 2006. 3(7): p. 390-407. 4. Rath, H.C., et al., Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun, 2001. 69(4): p. 2277-85. 5. Elson, C.O., et al., Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann N Y Acad Sci, 1998. 859: p. 85-95. 6. Harper, P.H., et al., Role of the faecal stream in the maintenance of Crohn's colitis. Gut, 1985. 26(3): p. 279-84. 7. Rutgeerts, P., et al., Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet, 1991. 338(8770): p. 771-4. 8. Dave, M., et al., Opportunistic Infections Due to Inflammatory Bowel Disease Therapy. Inflamm Bowel Dis, 2013. 9. Ben-Horin, S. and Y. Chowers, Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther, 2011. 33(9): p. 987-95. 10. Hoentjen, F., et al., Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut, 2003. 52(12): p. 1721-7. 11. Kang, S.S., et al., An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med, 2008. 5(3): p. e41. 12. Madsen, K.L., et al., Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology, 2000. 118(6): p. 1094-105. 
Holiday Study  Page 31  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  13. Khan, K.J., et al., Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol, 2011. 106(4): p. 661-73. 14. Wang, S.L., Z.R. Wang, and C.Q. Yang, Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med, 2012. 4(6): p. 1051-1056. 15. Ohkusa, T., et al., Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol, 2010. 105(8): p. 1820-9. 16. Uehara, T., et al., Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. J Gastroenterol Hepatol, 2010. [ADDRESS_464285] 1: p. S62-6. 17. Terao, S., et al., Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis. Digestion, 2011. 83(3): p. 198-203. 18. Turner, D., et al., Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report. J Crohns Colitis, 2014. 19. Iliev, I.D., et al., Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science, 2012. 336(6086): p. 1314-7. 20. Barclay, G.R., et al., The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol, 1992. 27(3): p. 196-200. 21. Zwolinska-Wcislo, M., et al., Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol, 2009. 60(1): p. 107-18. 22. Dollive, S., et al., Fungi of the Murine Gut: Epi[INVESTIGATOR_371077]. PLoS One, 2013. 8(8): p. e71806. 23. Wellmann, W. and F.W. Schmidt, Intestinal lavage in the treatment of Crohn's disease: a pi[INVESTIGATOR_799]. Klin Wochenschr, 1982. 60(7): p. 371-3. 24. Wellmann, W., P.C. Fink, and F.W. Schmidt, Whole-gut irrigation as antiendotoxinaemic therapy in inflammatory bowel disease. Hepatogastroenterology, 1984. 31(2): p. 91-3. 25. O'Brien, C.L., et al., Impact of colonoscopy bowel preparation on intestinal microbiota. PLoS One, 2013. 8(5): p. e62815. 26. Prantera, C., et al., An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol, 1996. 91(2): p. 328-32. 27. Sutherland, L., et al., Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut, 1991. 32(9): p. 1071-5. 28. Ursing, B., et al., A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology, 1982. 83(3): p. 550-62. 29. McKenna, P., et al., The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathogens, 2008. 4(2): p. 8. 30. Shieh, F.K., et al., MiraLAX-Gatorade bowel prep versus GoLytely before screening colonoscopy: an endoscopic database study in a community hospi[INVESTIGATOR_307]. J Clin Gastroenterol, 2012. 46(10): p. e96-e100. 31. Harvey, R.F. and Bradshaw, J.M., A simple index of Crohn’s-dease activity. The Lancet, 1980, March 8: p. 514. 32. Vermeire, S., et al., Correlation between the Crohn’s Disease Activity and Harvey–Bradshaw Indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol, 2010. 8(4): p. 357-363. 33. Thia, K., et al., Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis, 2011. 17(1): p. 105-11. 34. Vermeire, S., G. Van Assche, and P. Rutgeerts, Laboratory markers in IBD: useful, magic, or unnecessary toys. Gut, 2006. 55: p. 436-31. 35. Roseth, A.G., et al., Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scandinavian Journal of Gastroenterology, 1992. 27(9): p. 793-8. 36. Roseth, A.G., E. Aadland, and K. Grzyb, Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2004. 39(10): p. 1017-20. 
Holiday Study  Page 32  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  37. Roseth, A.G., et al., Assessment of disease activity in ulcerative colitis by [CONTACT_371141], a novel granulocyte marker protein. Digestion, 1997. 58(2): p. 176-80. 38. Walkiewicz, D., et al., Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflammatory Bowel Diseases, 2008. 14(5): p. 669-673. 39. Roseth, A.G., et al., Assessment of disease activity in ulcerative colitis by [CONTACT_371141], a novel granulocyte marker protein. Digestion, 1997. 58(2): p. 176-80. 40. Lin, J.F., et al., Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis, 2014. 20(8): p. 1407-15. 41. Sipponen, T., et al., Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis, 2008. 14(10): p. 1392-8. 42. Caporaso, J.G., et al., QIIME allows analysis of high-throughput community sequencing data. Nat Methods, 2010. 7(5): p. 335-6. 43. Su, C., et al., A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology, 2004. 126(5): p. 1257-69. 44. Sandborn, W.J., et al., Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med, 2007. 146(12): p. 829-38. 45. Sandborn, W.J., et al., Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med, 2013. 369(8): p. 711-21. 46. Lozupone, C., M. Hamady, and R. Knight, UniFrac--an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinformatics, 2006. 7(371). 47. Lozupone, C. and R. Knight, UniFrac: a new phylogenetic method for comparing microbial communities. Applied & Environmental Microbiology, 2005. 71(12): p. 8228-35. 48. Ciprofloxacin. Drugs@FDA. Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019537s073,020780s030lbl.pdf. Accessed February 18, 2015.  49. Vancocin (Vancomycin hydrochloride). DailyMed. U.S. National Library of Medicine, NIH Web site. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a078d9c2-f89c-4f9f-8ded-60ffb2983c3f&. Accessed February 18, 2015. 50. Neomycin sulfate. DailyMed. U.S. National Library of Medicine, NIH Web site. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=777dbfab-f83e-4738-ae1e-78619a9f82a7. Accessed April 1, 2015. 51. Diflucan (fluconazole). Drugs@FDA. Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019949s060,020090s044lbl.pdf. Accessed April 1, 2015.  52. GoLytely™. Drugs@FDA. Food and Drug Administratino Web site. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019011s025lbl.pdf. Accessed April 20, 2015.    
Holiday Study  Page 33  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  16 Appendix A: Adverse Reactions 16.1 Ciprofloxacin Common reactions (>5%) Occasional Reactions (1% to 5%) Rare but Serious Reactions (<1%)   Nausea, diarrhea, abnormal liver function tests, vomiting, rash Body: headache, abdominal pain/discomfort, foot pain, pain, pain in extremities    Cardiovascular: palpi[INVESTIGATOR_332], atrial flutter, ventricular ectopy, syncope, hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis, phebitis, tachycardia, migraine, hypotension 
   Central nervous system: restlessness, dizziness, lightheadedness, insomnia, nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive seizures, grand mal convulsion, lethargy, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression, paresthesia, abnormal gain    Gastrointestinal: painful oral mucosa, oral candidiasis, dysphagia, intestinal perforation, gastrointestinal bleeding, cholestatic jaundice, hepatisis    Hemic/Lymphatic: lymphadenopathy, petechia    Metabolic/Nutritional: amylase increase, lipase increase, hyperglycemia, hypoglycemia    Musculoskeletal*: arthalgia or back pain, joint stiffness, achiness, neck or chest pain, flare up of gout, muscle weakness    Renal/Urogenital: interstitial nephritis, nephritis, renal failure, polyuria, urinary retention, urethral bleeding, vaginitis, acidosis, breast pain    Respi[INVESTIGATOR_696]: dyspnea, epi[INVESTIGATOR_371078], laryngeal or pulmonary edema, hiccough, hemoptysis, bronchospasm, pulmonary embolism 
Holiday Study  Page 34  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371142]/Hypersensitivity: allergic reaction, pruritis, urticaria, photosensitivity/phototoxicity reaction, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpi[INVESTIGATOR_371], erythema nodosum, sweating    Senses: blurred vision, disturbed vision (changes in color perception, overbrightness of lights), decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste, chromatopsia  16.2 Vancomycin Common Reactions (>5%) Occasional Reactions (1% to 5%) Rare but Serious Reactions (<1%) Body: pyrexia, edema peripheral, fatigue Renal: nephrotoxicity including renal failure, renal impairment, increased blood creatinine Ototoxicity: hearing loss (associated with intravenous administration), vertigo, dizziness, tinnitus Gastrointestinal: nausea, abdminal pain, vomiting, diarrhea, flatulence   Hematopoetic: reversible neutropenia (associated with intraveous administration), thrombocytopenia Infections: urinary tract infection   Miscellaneous: anaphylaxis, drug fever, chills, nausea, eosinphilia, rash, Stevens-Johnson syndrome, toxic epi[INVESTIGATOR_371079], vasculitis Metabolism: hypokalemia     Musculoskeletal: back pain     Nervous system: headache     16.3 Neomycin Common Reactions (>5%) Occasional Reactions (1% to 5%) Rare but Serious Reactions (<1%)     Neurological: ototoxicity, respi[INVESTIGATOR_4939], neuromuscular blockage     Renal: nephrotoxicity, including numbness, skin tingling, muscle twitching and convulsions     Musculoskeletal: aggravation of muscle weakness in patients with myasthenia gravis or parkinsonism 
Holiday Study  Page 35  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371143]: fungal overgrowth, malabsorption syndrome for various substances, including fat, nitrogen, cholesterol, carotene, glucose, xylose, lactose, sodium, calcium, cyanocobalamin and iron  16.4 Fluconazole Common Reactions (>5%) Occasional Reactions (1% to 5%) Rare Reactions (<1%)   Body: skin rash, headache Hepatic: hepatotoxicity with no relation to daily dose, duration of therapy, age, or sex   Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain Immunological: anaphylaxis, including angioedema, face edema and pruritus   
                Cardiovascular: prolonged QT interval, torsade de pointes   Central Nervous System: dizziness, seizures   Hematopoietic and Lymphatic: leukopenia, including neutropenia and agranulocytosis, thrombocytopenia   Metabolic: hypercholesterolemia, hypertriglyceridemia, hypokalemia   Gastrointestinal: Cholestasis, dry mouth, hepatocellular damage, dyspepsia   Musculoskeletal: myalgia   Skin: acute generalized exanthematous-pustulosis, drug eruption, increased sweating, exfoliative skin disorders including Stevens-Johnson syndrome and toxic epi[INVESTIGATOR_194], alopecia   Miscellaneous: taste perversion, insomnia, paresthesia, somnolence, tremor, vertigo  16.5 Miralax (PEG 3350) Common Reactions (>5%) Occasional Reactions (1% to 5%) Rare but Serious Reactions (<1%) Nausea, abdominal fullness, bloating Abdominal cramps, vomiting, anal irritation Immunological: urticaria, rhinorrhea, dermatitis, anaphylaxis     In patients > 60 years-old: upper GI bleeding from Mallory-Weiss tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, "butterfly-like" infiltrates on chest X-ray after vomiting and aspi[INVESTIGATOR_371080] 36  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371143]: cardiac arrhythmia, tonic-clonic seizures and/or generalized loss of consciousness associated with electrolyte abnormalities  16.6 Promethazine (frequencies are not defined by [CONTACT_80669]) Common Reactions Rare but Serious Reactions CNS: drowsiness/sedation and confusion (use caution with performing tasks requiring mental alertness such as operating machinery or driving) Cardiac: cardiac conduction abnormalities; abnormal blood pressure (use with caution for people who have history of stroke, heart disease, and concurrent use of BP meds)  Derm: photosensitivity and skin pi[INVESTIGATOR_371] (slate gray), avoid prolonged sun exposure Neuro: slow abnormal movements, increased rigidity, tongue protrusion, restlessness, mental status change, fever, muscle rigidity, autonomic instability, hallucinations, seizures Misc: constipation, dry mouth, runny nose, blurred vision, urinary retention, temperature regulation Local: injection site reactions (burning, edema, erythema, pain), abscess, local tissue destruction, clots  Misc: cholestatic jaundice, hormone imbalance, abnormal platelets, increased risk for infection, loss of breathing (only seen in infants), allergic reaction    
Holiday Study  Page 37  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  17 Appendix B: Investigational Drug Service Documentation 
 UniversityofPennsylvaniaͲINVESTIGATIONALDRUGSERVICEͲPerelmanSchoolofMedicineMain:  [ADDRESS_464286] (Maloney Bldg, Ground Floor) | Satellite:  [ADDRESS_464287] (1 Mutch Bldg) | Philadelphia, PA 19104Protocol Title:An Open-Label Pi[INVESTIGATOR_371081]’s Disease             REVISED JULY 2015 VERSION 3Investigator:Albenberg, Lindsey, DOSponsor: Sponsor ID:pendingSubjects:Total of 20 outpatients to be enrolledDetail/Narrative:For each subject, IDS would (a) purchase commercial vancomycin for injection and compound oral syringes, to administer as 500mg QID on Days 1-14), packaged as 14 'daily' sets of 4; (b) dispense a 4-day course of ciprofloxacin, packaged as individual 'AM' and 'PM' bottles together with the vancomycin syringes; c) dispense  neomycin daily for 3 days; (d) prepare and dispense a single 8.3oz bottle of Miralax(R) ready to drink, along with one 20mg dose of bisacodyl; then (e) mail everything to the subject's home, 15 days prior to scheduled study visit 1 in CTRC.  Quantities below are based on 20 completed courses plus enough overage for 2 additional courses (for loss, replacement, repeating missed doses, etc); if not needed then overall costs may be less.  For FLUCONAZOLE, supplies & manufacturing assume enough for 11 active and 11 placebo courses, encapsulated for blinding purposes, based on a 400mg once/daily dose.Actual enrollment may vary; as a service center the IDS applies user fees for dispensing or drug preparation at the time those expenses actually occur.ActivityCostUnitsTotal*NOTEͲTHISISANAPPROXIMATIONOFCOSTSBASEDONCURRENTPRICES,NOTA'CONTRACT'*Estimate#1508Date Printed7/21/[ADDRESS_464288] (this is just an 'average' cost assuming a subject who completes the entire study) ............................$ 3 3 5 . 7 0TOTAL assuming all subjects above complete treatment (note - for budget guidance only - actual enrollment may vary) ............................$18,082.00Protocol And Inventory Maintenance (Per MONTH) $25.50 18.00 $459.00$1,155.00 1 $1,155.00Study Initiation (procedures, product formulation, randomization scheme, planning, meetings, etc.)Materials:$61.00 3.00Manufacturing (Per 100 Caps): placebo fluconazole$183.00$3.00 1.00Drug Purchase$3.00$13.00 616.00Drug Purchase$8,008.00$23.00 4.00Drug Purchase$92.00$119.00 4.00Drug Purchase$476.00$137.00 10.00Drug Purchase$1,370.00$12.00 22.00Drug Purchase$264.00$61.00 3.00Manufacturing (Per 100 Caps): blinded fluconazole$183.00Preparation and DispensationPrepare/dispense fluconazole (14 day course, 14 bottles); collect back used bottles to document compliance.$29.55 20.00 $591.00Prepare/dispense neomycin (3-day course, as 9 bottles); collect back used bottles to document compliance.$20.85 20.00 $417.00Prepare/dispense Miralax™ (8.3oz) with dosing cup and a 20mg dose of bisacodyl $20.85 20.00 $417.00Compound 1,120mL of oral vancomycin suspension (500mg/20mL concentration), then draw up into 56 individual oral syringes, hand-label and package into 14 separate ziploc bags (labeled as Day 1 through Day 14).  Includes cost of suspending agents $(119/gallon), syringes ($92/100), labour, etc.$184.25 20.00 $3,685.00UPS shippi[INVESTIGATOR_007] (estimated - note this is a pass-through expense) $12.00 20.00 $240.00Prepare/dispense ciprofloxacin (4-day course as 8 bottles) $20.85 20.00 $417.00Study Closure (copi[INVESTIGATOR_014], record archival, return or destroy supplies, etc.) $122.00 1 $122.00
Page 1 of 2

Holiday Study  Page 38  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]   UniversityofPennsylvaniaͲINVESTIGATIONALDRUGSERVICEͲPerelmanSchoolofMedicineMain:  [ADDRESS_464289] (Maloney Bldg, Ground Floor) | Satellite:  [ADDRESS_464290] (1 Mutch Bldg) | Philadelphia, PA 19104Study Initiation costs (everything that occurs BEFORE first enrollment - this cost occurs regardless of enrollment) ...$1,155.00DRUG PURCHASE COSTS (PASS-THROUGH EXPENSE) - subject to change, prices not guaranteed .............$10,213.00
Business Admin. address and phone:Business Admin. SignatureDate:Account Number (26-digits - call if you need to use a different format/system)Business Admin. E-MailPrepared by: [CONTACT_371144], PharmD, MSDate: 4/15/2015Additional Information:Drug purchases are a pass-through expense at time of purchase, separate from user fees and prices are not guaranteed.  Purchases listed above include vancomycin injection ($13/1gm vial x 616 vials), ciprofloxacin 750mg tabs ($23/btl of 50 x 4 btls), neomycin 500mg tabs ($119/100 x 4 btls), fluconazole 200mg tabs ($137/30 x 10 btls), Miralax® ($12 ea x 22 jars, 8.3oz each), bisacodyl 5mg tabs ($3/100 x 1 btl)NOTE: Business manager should complete & return to IDS before start.  Account# needed before ANY PURCHASES.  If project not funded yet, an alternate account should be provided.  This ESTIMATE is subject to change if actual IDS costs or sponsor requirements change.  The IDS is a service center subject to OMB-A21 and required to adjust its fees periodically to reflect actual cost of services.  Reduced monthly fees may apply for materials stored after close of a trial
Business Admin. Embossment Below:                                                                                             IRB #:
Page 2 of 2

Holiday Study  Page 39  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  18 Appendix C: CCFA-BMRP Sponsor Guidelines 
 

Holiday Study  Page 40  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371145] 41  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371145] 42  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371146] 43  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371147] 44  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_371148] 45  
V10.0.20170811 CONFIDENTIAL This material is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  1. Sheehan, D., C. Moran, and F. Shanahan, The microbiota in inflammatory bowel disease. J Gastroenterol, 2015. 50(5): p. 495-507. 2. Chehoud, C., et al., Fungal Signature [CONTACT_371149]. Inflamm Bowel Dis, 2015. 3. Shen, T.C., et al., Engineering the gut microbiota to treat hyperammonemia. J Clin Invest, 2015. 125(7): p. 2841-50. 4. Dethlefsen, L. and D.A. Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A, 2011. [ADDRESS_464291] 1: p. 4554-61. 5. Albenberg, L., et al., Correlation Between Intraluminal Oxygen Gradient and Radial Partitioning of Intestinal Microbiota in Humans and Mice. Gastroenterology, 2014. 6. Vermeire, S., G. Van Assche, and P. Rutgeerts, Laboratory markers in IBD: useful, magic, or unnecessary toys. Gut, 2006. 55: p. 436-31. 7. Roseth, A.G., E. Aadland, and K. Grzyb, Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2004. 39(10): p. 1017-20. 8. Gaya, D.R., et al., Faecal calprotectin in the assessment of Crohn's disease activity. Qjm, 2005. 98(6): p. 435-41. 9. Walkiewicz, D., et al., Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflammatory Bowel Diseases, 2008. 14(5): p. 669-673. 10. Dollive, S., et al., Fungi of the Murine Gut: Epi[INVESTIGATOR_371077]. PLoS One, 2013. 8(8): p. e71806. 11. Caporaso, J.G., et al., QIIME allows analysis of high-throughput community sequencing data. Nat Methods, 2010. 7(5): p. 335-6. 12. Hoffmann, C., et al., Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One, 2013. 8(6): p. e66019.   